Literature DB >> 30785013

Successful treatment of psoriasis induced by immune checkpoint inhibitors with apremilast.

Davide Fattore1, Maria Carmela Annunziata2, Luigia Panariello2, Claudio Marasca2, Gabriella Fabbrocini2.   

Abstract

Entities:  

Keywords:  Apremilast; Immune checkpoint inhibitors; Immune-related adverse events; Nivolumab; Psoriasis

Year:  2019        PMID： 30785013     DOI： 10.1016/j.ejca.2019.01.010

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  5 in total

Review 1.  Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.

Authors:  Maria Vastarella; Gabriella Fabbrocini; Vincent Sibaud
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

2.  Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report.

Authors:  Maria Anna Siciliano; Stefano Dastoli; Maria d'Apolito; Nicoletta Staropoli; Pierfrancesco Tassone; Pierosandro Tagliaferri; Vito Barbieri
Journal:  Front Oncol       Date:  2020-10-14       Impact factor: 6.244

Review 3.  Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.

Authors:  Laura C Cappelli; Clifton O Bingham
Journal:  Arthritis Rheumatol       Date:  2021-03-05       Impact factor: 10.995

Review 4.  Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors.

Authors:  Jennifer Choi; Ronald Anderson; Ada Blidner; Tim Cooksley; Michael Dougan; Ilya Glezerman; Pamela Ginex; Monica Girotra; Dipti Gupta; Douglas Johnson; Vickie R Shannon; Maria Suarez-Almazor; Bernardo L Rapoport; Mario E Lacouture
Journal:  Support Care Cancer       Date:  2020-08-27       Impact factor: 3.603

5.  Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Yixuan Yu; Yang Zhou; Xu Zhang; Kexin Tan; Jiabin Zheng; Jia Li; Huijuan Cui
Journal:  Front Oncol       Date:  2022-07-15       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.